COGENTIN INJECTION Rx
Generic Name and Formulations:
Benztropine mesylate 1mg/mL; soln for IM or IV inj.
Indications for COGENTIN INJECTION:
Adjunct in Parkinsonism, drug-induced extrapyramidal disorders.
Parkinsonism: initially 0.5–1mg at bedtime. May increase by 0.5mg at 5–6 day intervals; max 6mg daily. Extrapyramidal disorders: 1–4mg 1–2 times daily. Acute dystonic reactions: 1–2mg IM or IV.
See Contraindications. Use cautiously in older children.
Children <3yrs old.
Tardive dyskinesia: not recommended. Narrow-angle glaucoma. Tachycardia. Psychosis. Prostatic hypertrophy. GI or GU obstruction. Chronically ill. Alcoholics. CNS disease. Exposure to extreme heat. Elderly. Pregnancy.
Paralytic ileus, hyperthermia, heat stroke with phenothiazines, tricyclic antidepressants. Antagonizes psychotropics.
Anticholinergic and antihistaminic effects, weakness, confusion, anhidrosis, excitement, GI upset, depression, lethargy, heat stroke, dysuria, toxic psychosis, rash.
Tabs formerly known under the brand name Cogentin.
Tabs—contact supplier; Amps—(5 x 2mL)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities